by IR Team | Mar 8, 2021 | News
AXIM Biotechnologies (OTCQB:AXIM) has completed point-of-care clinical trials on its ImmunoPass rapid test that semi-quantitatively measures levels of COVID-19 neutralizing antibodies. The test aims to help understand COVID-19 immunity, validate vaccine’s...
by IR Team | Feb 28, 2021 | News
The CDC estimates that in the past 20 years, vaccines have saved more that 21 million lives. There are many different types of vaccines that provide protection against infectious diseases. Some examples of diseases for which vaccines elicit protective immunity include...
by IR Team | Feb 7, 2021 | News
John Huemoeller, CEO of AXIM Biotechnologies, an international healthcare solutions company based in San Diego targeting oncological and COVID-19 research, discusses three first-of-their-kind COVID-19 neutralizing antibody tests. They have developed the world’s first...
by IR Team | Feb 3, 2021 | News
AXIM Biotechnologies (OTCQB:AXIM) announces the start of clinical trials for ImmunoPass, the company’s rapid point-of-care test that semi-quantitatively measures levels of neutralizing antibodies to COVID-19. Measuring neutralizing antibodies in people after...
by IR Team | Jan 28, 2021 | News
IPM spoke with AXIM Biotech CEO John Huemoeller to see how his firm are going about seeking patent protection for its Covid-19 tests. Obtaining IP rights protections for Covid-19 related treatments and tests is the number one public health priority right now.The race...
by IR Team | Dec 15, 2020 | News
In what U.S. FDA commissioner Stephen Hahn billed as “a major milestone” in testing for the COVID-19 pandemic, the FDA has granted an emergency use authorization (EUA) to Ellume Ltd., of East Brisbane, Australia, for the company’s COVID-19 home test. The rapid...
